Albuminuria: a target for clinical trials in kidney disease?

Affiliations

Comment

Richard J Glassock. Nat Rev Nephrol. 2019 May.

. 2019 May;15(5):257-258.

doi: 10.1038/s41581-019-0123-x.

No abstract available

Comment on

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.
Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration. Coresh J, et al. Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. doi: 10.1016/S2213-8587(18)30313-9. Epub 2019 Jan 8. Lancet Diabetes Endocrinol. 2019. PMID: 30635225 Free PMC article.
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.
Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA; Chronic Kidney Disease Epidemiology Collaboration. Heerspink HJL, et al. Lancet Diabetes Endocrinol. 2019 Feb;7(2):128-139. doi: 10.1016/S2213-8587(18)30314-0. Epub 2019 Jan 8. Lancet Diabetes Endocrinol. 2019. PMID: 30635226

1. Cravedi, P. & Remuzzi, G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease Br. J. Clin. Pharmacol. 76, 516–523 (2013). - PubMed - PMC
1. Eijkelkamp, W. B. et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nephrol. 18, 1540–1546 (2007). - DOI
1. Glassock, R. J. Control of albuminuria in overt diabetic nephropathy: durability counts. Nephrol. Dial. Transplant. 31, 1371–1373 (2016). - DOI
1. Fried, L. F. & Lewis, J. Albuminuria is not an appropriate therapeutic target in patients with CKD: the con view. Clin. J. Am. Soc. Nephrol. 10, 1089–1093 (2015). - DOI
1. Lambers Heerspink, H. J. & Gansevoort, R. T. Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view. Clin. J. Am. Soc. Nephrol. 10, 1079–1088 (2015). - DOI